Skip to content

A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans

Using a Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05903885
Enrollment
1200
Registered
2023-06-15
Start date
2023-10-02
Completion date
2026-10-01
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Prevention

Keywords

Prevention, Department of motor vehicles, Cross-sectoral partnership, African Americans, Screening

Brief summary

African Americans face racial disparities in colorectal cancer (CRC), with lower screening rates and higher incidence and mortality rates. To address this gap and improve CRC screening rates, investigators aims to recruit a total of 1,200 African American participants aged 45-75 during their visits to the DMV, 4606 N 56th St Ste100, Omaha, for CRC screening. All participants will receive a free Fecal Immunochemical Test (FIT) kit with a prepaid return envelope, a culturally tailored educational brochure, reminder text messages and calls, and post-FIT navigation support for participants with positive results or without family doctor/insurance. Kits are returned to a designated Nebraska Medicine lab for testing, and test results will be mailed to participants within 14-21 days. Participants will be assigned to one of two groups: the on-site distribution group or the on-site distribution group with social media advertising group. The social media advertising group will additionally be exposed to targeted ads on platforms like Facebook, Instagram, and YouTube to increase awareness and potentially improve participation rates. The study will compare FIT kit return rates, positive screening rates, and completion rates of follow-up colonoscopies after positive FIT results between the two groups.

Detailed description

African Americans face racial disparities in colorectal cancer (CRC), with lower screening rates and higher incidence and mortality rates. The American Cancer Society reported that African Americans are about 20% more likely to have CRC and 40% more likely to die from it compared to other racial groups. The main reasons for high CRC incidence and mortality for African Americans are structural barriers in access to quality healthcare and timely screening that can be attributed in large part to historical and persistent structural racism in the U.S. To address this gap and improve CRC screening rates among African Americans, this study will partner with the Department of Motor Vehicles (DMV) to recruit African Americans eligible for CRC screening during their regular visits to the DMV. Investigators will recruit 1,200 participants aged 45-75 for CRC screening. Upon consent, participants' demographic and screening-related information will be collected via a paper-based registration survey (e.g., name, age, gender, race/ethnicity, address, healthcare access, recent CRC screening history, smoking status, and personal/family history of CRC). All participants will receive a free Fecal Immunochemical Test (FIT) kit with a prepaid return envelope, a culturally tailored educational brochure, reminder text messages and calls. Participants will be assigned to one of two groups: the on-site distribution group or the on-site distribution group with social media advertising group. The social media advertising group will additionally be exposed to targeted ads on platforms like Facebook, Instagram, and YouTube from August 19, 2024, to October 29, 2024, to increase awareness and potentially improve participation rates. Kits are returned to a designated Nebraska Medicine lab, and test results will be mailed to participants within 14-21 days. Follow-up services, including assistance with scheduling colonoscopies and applying for financial support programs, will be provided by a health navigator at Charles Drew Health Center for participants with positive results or those without health insurance or a primary care provider. Outcomes (screening completion rate and positive results) will be compared between the onsite and onsite with social media advertising groups, controlling for other covariates (age, gender, income, previous screening, smoking status, healthcare access, and health beliefs). The study will also assess the cost-effectiveness of each strategy and the completion rate of follow-up colonoscopies after receiving positive FIT results. Participants' perceptions and beliefs about screening will be collected via an online survey.

Interventions

OTHEROn-site Fecal Immunochemical Test (FIT) Kit Distribution

Participants will receive home based Fecal Immunochemical Test (FIT) kit directly at the Department of Motor Vehicles (DMV) location at 4606 N 56th St Suite 100, Omaha, NE 68104, by research staff.

OTHEROn-site With Social Media Advertising Fecal Immunochemical Test (FIT) Kit Distribution

Participants will receive home-based Fecal Immunochemical Test (FIT) kits directly at the Department of Motor Vehicles (DMV) location at 4606 N 56th St Suite 100, Omaha, NE 68104, by research staff supplemented by exposure to targeted social media advertisements.

Sponsors

University of Nebraska
Lead SponsorOTHER
Robert Wood Johnson Foundation
CollaboratorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Intervention model description

The study aims to enroll 600 participants to each of two groups to evaluate strategies in improving colorectal cancer screening rates among African Americans. The groups are the on-site group and the on-site group with social media advertising. The latter group will have exposure to targeted ads on Facebook, Instagram, and YouTube which will run from August 19 to October 29, 2024. The social media campaign will target African American residents of Omaha, aged 45-75. Both groups will be given fecal immunochemical test (FIT) kits, a prepaid return envelope, and an educational brochure when visiting the Department of Motor Vehicles (DMV), 4606 N 56th St Suite 100, Omaha, NE 68104. Both groups will also be given reminder messages and post-FIT navigation support, if needed. Participants' information and perceptions will be collected via surveys. FIT return rate, positive screening rate, and follow-up colonoscopy completion rate will be compared between groups, controlling for covariates.

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Self-identification as Black or African American * Between 45 and 75 years old * Not up-to-date with colorectal cancer (CRC) screening per guidelines * Willingness to provide contact information for follow-up * Ability to speak, read, and write English * Current residency in Douglas County, NE.

Exclusion criteria

* History of colorectal cancer (CRC) * History of adenomas (precancerous polyps) or inflammatory bowel disease * Family history of colorectal cancer (CRC)

Design outcomes

Primary

MeasureTime frameDescription
Fecal Immunochemical Test Kit Return Rate6 months from date of FIT distributionThe fecal immunochemical test kit (FIT) return rate is the proportion of participants who have completed the screening by returning the FIT kits.

Secondary

MeasureTime frameDescription
Fecal Immunochemical Test (FIT) Kit Positive Rate6 months from date of FIT distributionThe fecal immunochemical test (FIT) kit positive rate is the proportion of participants who have positive FIT kit results.
Follow-up Colonoscopy Completion Rate6 months from date of positive FIT result notificationThe follow-up colonoscopy completion rate is the proportion of participants with positive FIT results who complete a follow-up colonoscopy.

Countries

United States

Contacts

CONTACTJungyoon Kim, PhD
jungyoon.kim@unmc.edu(402) 552-7235
PRINCIPAL_INVESTIGATORJungyoon Kim, PhD

University of Nebraska

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026